Symptoms and Quality of Life (QoL) After Palliative Pelvic Radiation of Prostate and Rectal Cancers

Sorlandet Hospital HF98 enrolled

Overview

The purpose of this study is to assess the effect of palliative pelvic radiation on symptoms and quality of life among patients with incurable prostate and rectal cancer.

With the aging population, the prevalence of cancer is on the rise, leading to an increased demand for effective palliative treatment. There is little scientific information describing the effects of palliative radiotherapy among patients treated for soft-tissue tumors of the pelvis. This is a treatment that is used relatively frequently, but delivered heterogeneously since the optimum fractionation schedule has yet to be established. This study aims to define the effects of one such fractionation schedule (3Gy x 10-13) and thus, establish a foundation for future fractionation studies.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Prostatic Neoplasms Rectal Neoplasms

Interventions

Palliative pelvic soft-tissue radiation (external beam)RADIATION

3 Gy x 10-13 (range 30 - 39 Gy total)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Age ≥ 18 years * Histologically or cytologically proven adenocarcinoma of the prostate or rectosigmoid colon. * Incurable disease (hormone-resistant in cases of prostate cancer) * Life expectancy \> 3 months * Symptomatic soft-tissue pelvic tumor mass (primary, recurrence or metastases) * Planned fractionated radiotherapy (3Gy x 10-13) * Written informed consent Exclusion criteria: * Unable to fill out questionnaires (due to language or cognitive barriers) * New systemic tumor-targeted treatment (hormone manipulation, chemotherapy, monoclonal antibodies, etc.) started within four weeks of baseline or during the 6 weeks immediately following pelvic radiotherapy. * Previous pelvic radiotherapy * The presence of a second primary pelvic cancer or other cancer requiring treatment * Currently receiving treatment with an investigational drug

Locations (8)

Stavanger University Hospital

Stavanger, Rogaland, Norway

Ålesund Hospital

Ålesund, Norway

Nordland Hospital, Bodø

Bodø, Norway

Innlandet Hospital Trust, Gjøvik

Gjøvik, Norway

Outcomes

Primary Outcomes

Effect on patient's target symptom.

Time frame: at end of treatment and 6 weeks and 12 weeks after treatment completion

Secondary Outcomes

Effect on patient's QoL.

Time frame: at end of treatment and 6 and 12 weeks after treatment completion.

Time to improvement in patient's symptoms and QoL.

Time frame: at end of treatment and 6 and 12 weeks after treatment completion.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.